Echocardiographic Phenotype and Prognosis in Transthyretin Cardiac Amyloidosis
Overview
Authors
Affiliations
Aims: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. We sought to characterize the structural and functional echocardiographic phenotype across the spectrum of wild-type (wtATTR-CM) and hereditary (hATTR-CM) transthyretin cardiomyopathy and the echocardiographic features predicting prognosis.
Methods And Results: We studied 1240 patients with ATTR-CM who underwent prospective protocolized evaluations comprising full echocardiographic assessment and survival between 2000 and 2019, comprising 766 with wtATTR-CM and 474 with hATTR-CM, of whom 314 had the V122I variant and 127 the T60A variant. At diagnosis, patients with V122I-hATTR-CM had the most severe degree of systolic and diastolic dysfunction across all echocardiographic parameters and patients with T60AhATTR-CM the least; patients with wtATTR-CM had intermediate features. Stroke volume index, right atrial area index, longitudinal strain, and E/e' were all independently associated with mortality (P < 0.05 for all). Severe aortic stenosis (AS) was also independently associated with prognosis, conferring a significantly shorter survival (median survival 22 vs. 53 months, P = 0.001).
Conclusion: The three distinct genotypes present with varying degrees of severity. Echocardiography indicates a complex pathophysiology in which both systolic and diastolic function are independently associated with mortality. The presence of severe AS was independently associated with significantly reduced patient survival.
Biomarkers in Subclinical Transthyretin Cardiac Amyloidosis.
Gulati J, Pedretti R, Hendren N, Kozlitina J, Saelices L, Roth L Curr Heart Fail Rep. 2025; 22(1):8.
PMID: 39945945 DOI: 10.1007/s11897-025-00696-y.
Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.
Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D Orphanet J Rare Dis. 2025; 20(1):29.
PMID: 39819351 PMC: 11740649. DOI: 10.1186/s13023-025-03547-0.
Echocardiographic findings of patients with transthyretin amyloid cardiomyopathy.
Usuku H, Oike F, Kuyama N, Hirakawa K, Takashio S, Izumiya Y J Echocardiogr. 2024; 23(1):1-9.
PMID: 39729212 DOI: 10.1007/s12574-024-00672-w.
Chan N, Einstein A, Teruya S, Rodriguez C, Helmke S, Cuomo M Am J Cardiol. 2024; 237:60-64.
PMID: 39581521 PMC: 11761373. DOI: 10.1016/j.amjcard.2024.11.019.
Novel Insights into Non-Invasive Diagnostic Techniques for Cardiac Amyloidosis: A Critical Review.
Dicorato M, Basile P, Muscogiuri G, Carella M, Naccarati M, Dentamaro I Diagnostics (Basel). 2024; 14(19).
PMID: 39410653 PMC: 11475987. DOI: 10.3390/diagnostics14192249.